Access & reimbursement

Personalised Cancer Vaccines Clear Phase III
Intismeran autogene plus pembrolizumab reduced melanoma recurrence or death by 42% in the first positive Phase III trial of an individualised mRNA neoantigen therapy. The science has crossed an important threshold. Manufacturing, reimbursement and equitable delivery now become part of the clinical question.

Europe’s Preventable RSV Winter

HRR Testing Moves Upfront in Prostate Cancer

Barbados Made HIV Prevention Work

Endometrial Cancer Gets a Strong ADC Win

Divarasib Raises the KRAS G12C Bar

Ten Years of MS Data Make Delay Harder to Defend

One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.

Precision Oncology Has a Scale Problem

One in Eight Cancers Starts With an Infection
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
